T cell-derived IL-10 determines leishmaniasis disease outcome and is suppressed by a dendritic cell based vaccine

PLoS Pathog. 2013;9(6):e1003476. doi: 10.1371/journal.ppat.1003476. Epub 2013 Jun 27.

Abstract

In the murine model of Leishmania major infection, resistance or susceptibility to the parasite has been associated with the development of a Th1 or Th2 type of immune response. Recently, however, the immunosuppressive effects of IL-10 have been ascribed a crucial role in the development of the different clinical correlates of Leishmania infection in humans. Since T cells and professional APC are important cellular sources of IL-10, we compared leishmaniasis disease progression in T cell-specific, macrophage/neutrophil-specific and complete IL-10-deficient C57BL/6 as well as T cell-specific and complete IL-10-deficient BALB/c mice. As early as two weeks after infection of these mice with L. major, T cell-specific and complete IL-10-deficient animals showed significantly increased lesion development accompanied by a markedly elevated secretion of IFN-γ or IFN-γ and IL-4 in the lymph nodes draining the lesions of the C57BL/6 or BALB/c mutants, respectively. In contrast, macrophage/neutrophil-specific IL-10-deficient C57BL/6 mice did not show any altered phenotype. During the further course of disease, the T cell-specific as well as the complete IL-10-deficient BALB/c mice were able to control the infection. Furthermore, a dendritic cell-based vaccination against leishmaniasis efficiently suppresses the early secretion of IL-10, thus contributing to the control of parasite spread. Taken together, IL-10 secretion by T cells has an influence on immune activation early after infection and is sufficient to render BALB/c mice susceptible to an uncontrolled Leishmania major infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Dendritic Cells / immunology*
  • Interferon-gamma / genetics
  • Interferon-gamma / immunology
  • Interleukin-10 / genetics
  • Interleukin-10 / immunology*
  • Interleukin-4 / genetics
  • Interleukin-4 / immunology
  • Leishmania major / immunology*
  • Leishmaniasis Vaccines / immunology*
  • Leishmaniasis Vaccines / pharmacology
  • Leishmaniasis, Cutaneous / genetics
  • Leishmaniasis, Cutaneous / immunology*
  • Leishmaniasis, Cutaneous / pathology
  • Lymph Nodes / immunology
  • Mice
  • Mice, Inbred BALB C
  • Mice, Knockout
  • Th1 Cells / immunology*
  • Th1 Cells / pathology
  • Th2 Cells / immunology*
  • Th2 Cells / pathology

Substances

  • IL10 protein, mouse
  • Leishmaniasis Vaccines
  • Interleukin-10
  • Interleukin-4
  • Interferon-gamma

Grants and funding

This work was supported by grant MO418/9-3 from the German Research Foundation (DFG), Germany. TS was supported by the Interdisciplinary Center for Clinical Research, University of Würzburg, Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.